Popular
RGEN · Medicine & biotech · U.S.

Repligen

Makes filters and tools used to produce medicines from cells.

Company Health

60
/100
Mixed
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
14 of 25 · Okay
$7 of every $100 in sales was left as profit last year.
Is it growing?
6 of 25 · Poor
Sales shrank about 3% a year over the last 3 years.
Can it handle what it owes?
21 of 25 · Good
It would take about 2 years of the cash its business brings in to pay off everything it owes.
Does it bring in spare cash?
19 of 25 · Good
After paying for buildings and equipment, $13 of every $100 in sales was left as spare cash.

Who owns it

1 of 23 own it · 1 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Repligen’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $366 million in 2020 to $738 million in 2025, and it made a profit in 5 of the 6 years.
2025
Sales
$738 million
Profit
$48.9 million

Spare cash each year

It had cash to spare every year, ending with $93.9 million to spare in 2025.
2025
Spare cash
$93.9 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $2.95 billion, including $566 million in cash, and owed $844 million.

Key facts

From its yearly report for 2025.
Sales
$738 million
Profit
$48.9 million
Spare cash
$93.9 million
Cash in the bank
$566 million
Everything it owes
$844 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Feb 26, 2026
Figures from Repligen’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy